LOGIN
Sativex effective in alleviating pain and allodynia from neuropathy after 5-week follow up
September 2018
Sativex effective in alleviating pain and allodynia from neuropathy after 5-week follow up
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A
Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial
Pain. 2007 Dec 15;133(1-3):210-20Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
125 patients experiencing unilateral peripheral neuropathic pain and allodynia were randomly assigned to either treatment with sativex, a delta-9-tetrahydrocannabinol and cannabidiol (THC:CBD) endocannabinoid system modulator, or placebo. Patient-reported pain and allodynia severity, as well as the incidence of adverse events, were assessed at baseline and 5-week follow up. Results demonstrated th...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.